Key result
Small molecules targeting highly conserved noncoding RNA elements in viral genomes offer a promising strategy for developing antiviral therapies against pathogens like HIV, HCV, and SARS-CoV.
Answers are grounded in this paper and cite their sources.
Targeting highly conserved noncoding RNA elements in viral genomes with small molecules offers a promising strategy for developing novel antiviral therapies.
Highly conserved noncoding RNA (ncRNA) elements in viral genomes and transcripts offer new opportunities to expand the repertoire of drug targets for the development of antiinfective therapy. Ligands binding to ncRNA architectures are able to affect interactions, structural stability or conformational changes and thereby block processes essential for viral replication. Proof of concept for targeting functional RNA by small molecule inhibitors has been demonstrated for multiple viruses with RNA genomes. Strategies to identify antiviral compounds as inhibitors of ncRNA are increasingly emphasizing consideration of drug-like properties of candidate molecules emerging from screening and ligand design. Recent efforts of antiviral lead discovery for RNA targets have provided drug-like small molecules that inhibit viral replication and include inhibitors of human immunodeficiency virus (HIV), hepatitis C virus (HCV), severe respiratory syndrome coronavirus (SARS CoV), and influenza A virus. While target selectivity remains a challenge for the discovery of useful RNA-binding compounds, a better understanding is emerging of properties that define RNA targets amenable for inhibition by small molecule ligands. Insight from successful approaches of targeting viral ncRNA in HIV, HCV, SARS CoV, and influenza A will provide a basis for the future exploration of RNA targets for therapeutic intervention in other viral pathogens which create urgent, unmet medical needs. Viruses for which targeting ncRNA components in the genome or transcripts may be promising include insect-borne flaviviruses (Dengue, Zika, and West Nile) and filoviruses (Ebola and Marburg). WIREs RNA 2016, 7:726-743. doi: 10.1002/wrna.1373 For further resources related to this article, please visit the WIREs website.
No takes yet. Share an insight, caveat, or question.
Thomas Hermann (2016) conducted a review in Viral infections. Small molecules targeting viral RNA was evaluated. Small molecules targeting highly conserved noncoding RNA elements in viral genomes offer a promising strategy for developing antiviral therapies against pathogens like HIV, HCV, and SARS-CoV.
Synapse has enriched 10 related papers. Consider them for comparative context: